{"id":"statins-ezetimibe","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Myalgia or muscle pain"},{"rate":"1-3","effect":"Elevated liver transaminases"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Gastrointestinal upset"},{"rate":"<0.1","effect":"Rhabdomyolysis"}]},"_chembl":{"chemblId":"CHEMBL1138","moleculeType":"Small molecule","molecularWeight":"409.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, reducing intracellular cholesterol and upregulating LDL receptors for increased clearance. Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, preventing dietary and biliary cholesterol absorption. Combined, they provide complementary lipid-lowering effects through distinct mechanisms.","oneSentence":"Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis, while ezetimibe blocks intestinal cholesterol absorption, together lowering LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:39.494Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction"},{"name":"Primary and secondary prevention of coronary artery disease"}]},"trialDetails":[{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT07447648","phase":"","title":"Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","startDate":"2026-03","conditions":"Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography","enrollment":52},{"nctId":"NCT07445542","phase":"","title":"Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2021-12-18","conditions":"Hypercholesterolemia","enrollment":6927},{"nctId":"NCT07440381","phase":"PHASE3","title":"triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","status":"NOT_YET_RECRUITING","sponsor":"Heart Care Foundation","startDate":"2026-09","conditions":"Acute Coronary Syndromes, Secondary Prevention, Lipids","enrollment":600},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT06740552","phase":"","title":"Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-01-01","conditions":"Multivessel Coronary Artery Disease, Acute Myocardial Infarction (AMI)","enrollment":1862},{"nctId":"NCT07208006","phase":"NA","title":"Very Early PCSK9 Inhibition for Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-01","conditions":"Acute Myocardial Infarction (AMI)","enrollment":1518},{"nctId":"NCT05782777","phase":"NA","title":"Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-04-07","conditions":"Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation","enrollment":4310},{"nctId":"NCT05088759","phase":"NA","title":"Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-10-08","conditions":"Hyperlipemia, Mixed, ASCVD","enrollment":400},{"nctId":"NCT06431763","phase":"PHASE4","title":"A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-06-21","conditions":"Hypercholesterolemia","enrollment":402},{"nctId":"NCT07341958","phase":"NA","title":"INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-02-01","conditions":"Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)","enrollment":242},{"nctId":"NCT05579626","phase":"PHASE4","title":"Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)","status":"ENROLLING_BY_INVITATION","sponsor":"Seung-Whan Lee, M.D., Ph.D.","startDate":"2023-03-14","conditions":"Pre Diabetes, ASCVD","enrollment":4000},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT07255820","phase":"PHASE4","title":"Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol","enrollment":126},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT05910476","phase":"PHASE4","title":"Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-05-03","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":200},{"nctId":"NCT04755413","phase":"NA","title":"The Precision CAD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Coronary Artery Disease","enrollment":276},{"nctId":"NCT04626973","phase":"NA","title":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2021-01-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":3048},{"nctId":"NCT06005597","phase":"PHASE3","title":"Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-03-01","conditions":"Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":407},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT05614765","phase":"","title":"Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-07-08","conditions":"Dyslipidemias","enrollment":18000},{"nctId":"NCT06722521","phase":"PHASE4","title":"GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-09","conditions":"Primary Prevention, Vascular Calcification","enrollment":7435},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT07084259","phase":"PHASE4","title":"Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Hanyang University Seoul Hospital","startDate":"2025-07","conditions":"Coronary Artery Disease","enrollment":352},{"nctId":"NCT06647238","phase":"NA","title":"Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2024-11-05","conditions":"Hyperlipidemia, Coronary Artery Disease","enrollment":80},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT07036991","phase":"PHASE4","title":"Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-30","conditions":"Carotid Artery Stenosis","enrollment":406},{"nctId":"NCT06649240","phase":"NA","title":"Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-10-04","conditions":"Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL","enrollment":4016},{"nctId":"NCT03110432","phase":"","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2017-05-18","conditions":"Dyslipoproteinemias, Hypercholesterolemia, Familial, Familial Hypercholesterolemia - Homozygous","enrollment":1695},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":"ASCVD, Diabetes, Statin","enrollment":2000},{"nctId":"NCT05368545","phase":"NA","title":"Influence of Lipid Lowering on Impaired Coronary Flow","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2020-05-15","conditions":"Coronary Artery Disease","enrollment":109},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":"Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder","enrollment":200},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT05255094","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-11-03","conditions":"Hyperlipidemia","enrollment":464},{"nctId":"NCT05260411","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-01-26","conditions":"Hyperlipidemia","enrollment":246},{"nctId":"NCT06854523","phase":"NA","title":"Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)","status":"NOT_YET_RECRUITING","sponsor":"Yun Dai Chen","startDate":"2025-04-15","conditions":"Acute Myocardial Infarction","enrollment":300},{"nctId":"NCT05255458","phase":"PHASE3","title":"A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-11-04","conditions":"Hyperlipidemia","enrollment":122},{"nctId":"NCT06821711","phase":"NA","title":"Optimal LDL-C Target in High-risk Patients After PCI","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-02-20","conditions":"Chronic Coronary Syndrome, Acute Coronary Syndromes, Percutaneous Coronary Intervention","enrollment":12000},{"nctId":"NCT06784557","phase":"PHASE4","title":"Effect of Ezetimibe on Gut Microbiota","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-02-28","conditions":"Atherosclerotic Cardiovascular Disease With Dyslipidemia","enrollment":110},{"nctId":"NCT05845424","phase":"PHASE4","title":"High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2023-07-03","conditions":"Coronary Artery Calcification, Metabolic Syndrome, Dyslipidemias","enrollment":6000},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT04303377","phase":"PHASE2","title":"Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction","status":"WITHDRAWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-11-18","conditions":"ST-elevation Myocardial Infarction","enrollment":""},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT04807400","phase":"PHASE3","title":"Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-07","conditions":"Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol","enrollment":892},{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT06293417","phase":"NA","title":"To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-03-01","conditions":"T2DM (Type 2 Diabetes Mellitus), Dyslipidemias","enrollment":3958},{"nctId":"NCT06567418","phase":"","title":"Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-08-01","conditions":"Acute Coronary Syndrome","enrollment":10000},{"nctId":"NCT04701242","phase":"NA","title":"Ezetimibe Utilization Early After Acute Myocardial Infarction, \"EzAMI Trial\"","status":"RECRUITING","sponsor":"Cairo University","startDate":"2021-03-24","conditions":"Acute Myocardial Infarction, Dyslipidemias","enrollment":500},{"nctId":"NCT00651963","phase":"PHASE4","title":"Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-09","conditions":"Lipid Metabolism Disorder","enrollment":80},{"nctId":"NCT00092586","phase":"PHASE3","title":"Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":2904},{"nctId":"NCT00652847","phase":"PHASE4","title":"Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia","enrollment":1140},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00395603","phase":"PHASE3","title":"Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Cardiovascular Diseases, Diabetes Mellitus","enrollment":550},{"nctId":"NCT00328523","phase":"PHASE3","title":"TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06","conditions":"Hypercholesterolaemia, Hyperlipidaemia","enrollment":1496},{"nctId":"NCT05266586","phase":"PHASE2","title":"Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2022-03-09","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":119},{"nctId":"NCT00653523","phase":"PHASE3","title":"Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":151},{"nctId":"NCT00654095","phase":"PHASE3","title":"Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":146},{"nctId":"NCT00479713","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-01","conditions":"Hypercholesterolemia","enrollment":618},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT00395473","phase":"PHASE3","title":"Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-03","conditions":"Hypercholesterolemia","enrollment":141},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT05974345","phase":"","title":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":204691},{"nctId":"NCT04770389","phase":"PHASE2","title":"Randomized Study of Obicetrapib in Combination With Ezetimibe","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2021-02-23","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":112},{"nctId":"NCT06381947","phase":"PHASE4","title":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Salerno","startDate":"2024-05-01","conditions":"Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT05361421","phase":"PHASE4","title":"Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-07-19","conditions":"Cardiovascular Disease","enrollment":1200},{"nctId":"NCT05587621","phase":"NA","title":"Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)","status":"NOT_YET_RECRUITING","sponsor":"Jena University Hospital","startDate":"2024-04-01","conditions":"ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol","enrollment":300},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT04719221","phase":"PHASE4","title":"Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2021-03-01","conditions":"Clinical Trial, Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT01308203","phase":"PHASE4","title":"Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Daniel A. Siniawski","startDate":"2011-10","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":32},{"nctId":"NCT04826354","phase":"PHASE4","title":"Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2021-08-11","conditions":"Atheroscleroses, Coronary","enrollment":582},{"nctId":"NCT05765370","phase":"NA","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-03-24","conditions":"Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol","enrollment":4200},{"nctId":"NCT03933293","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-05-13","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT04173403","phase":"PHASE2","title":"A Long-term Study of AK102 in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-11-04","conditions":"Hypercholesterolemia","enrollment":796},{"nctId":"NCT04173793","phase":"PHASE2","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-11-18","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":109},{"nctId":"NCT04358432","phase":"PHASE2","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2020-05-13","conditions":"Hypercholesterolemia","enrollment":262},{"nctId":"NCT02534376","phase":"EARLY_PHASE1","title":"Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":63},{"nctId":"NCT04895098","phase":"","title":"Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD","status":"COMPLETED","sponsor":"Akrikhin","startDate":"2021-06-23","conditions":"Lipid Metabolism Disorders, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT05546398","phase":"","title":"SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2022-04-22","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":500},{"nctId":"NCT05613400","phase":"PHASE4","title":"Statin and Bone Health","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-13","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT01587235","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-03","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00726856","phase":"","title":"Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Dyslipidemia","enrollment":1200},{"nctId":"NCT01236430","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-02","conditions":"Hyperlipidemia","enrollment":200},{"nctId":"NCT00704535","phase":"","title":"Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia","enrollment":4105},{"nctId":"NCT00705081","phase":"","title":"Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-01","conditions":"Hypercholesterolemia","enrollment":453},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":266,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"statins, ezetimibe","genericName":"statins, ezetimibe","companyName":"Korea University Anam Hospital","companyId":"korea-university-anam-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis, while ezetimibe blocks intestinal cholesterol absorption, together lowering LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction, Primary and secondary prevention of coronary artery disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}